1.Clinical study on effect of Xingnao Yizhi Pills on vascular dementia
China Journal of Traditional Chinese Medicine and Pharmacy 2005;0(06):-
Objective:To observe the clinical effect of Xingnao Yizhi Pills on vascular dementia.Methods:Eighty-five patients suffering from vascular dementia were randomly divided into two groups,the treatment group(n=55)and the control group(n=30).The treatment group took a dose of 6g of Xingnao Yizhi Pills orally,twice a day.The control group was given 20ml Cerebrolysin with 250ml of 0.9%saline intravenous drip.They were also given 20ml Mailuoning and 0.5g of Cytidine Diphosphate Choline CDPC with 0.9%saline intravenous drip once a day.The treatment of the two groups lasted two months. Results:The total efficiency of the treatment group(92.7%)was obviously higher than that of the control group(73.3%)(P
2.Recombinant human growth hormone (rhGH) for the treatment of postoperative respiratory failure in surgical patients
Kaijiang YU ; Mingyan ZHAO ; Shukui DAI
Chinese Journal of General Surgery 2001;0(10):-
ObjectiveTo study the effect of recombinant human growth hormone (rhGH) on postoperative patients on mechanical ventilation.Methods Forty postoperative respiratory failure patients on mechanical ventilation were treated by rhGH 8?IU injection subcutaneously QD.ResultsThe time of mechanical ventilation of rhGH group was (30?12)?d, compared with that in 40 control patients (39?13)?d (t=2 538,P
3.The expressions of c-Met, VEGF, EGFR and HER-2 in the AFP-producing gastric cancer
Yu FANG ; Lin WANG ; Guimei LI ; Yu ZHANG ; Ningrong YANG ; Shukui QIN
China Oncology 2016;26(8):662-669
Background and purpose:Alpha fetoprotein (AFP)-producing gastric cancer (AFPGC) is considered to be a special type of gastric cancer. Currently, the effect on AFPGC is not as good as the common AFP-
negative gastric cancer. Therefore, it is very important to explore clinicopathological features of AFPGC cancer, to improve diagnosis and individualized treatment. This study is to investigate the expressions of hepatocyte growth factor receptor c (c-Met), vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER-2) in the AFPGC.Methods:A total number of 44 cases of AFPGC (serum AFP≥10 μg/L) tissues were selected as a test group. There were 30 cases of serum AFP≥200 μg/L. This study collected 30 cases of gastric cancer with normal AFP and 30 cases of hepatocellular carcinoma with increased AFP (serum AFP≥200 μg/L) as 2 control groups. The cases of the 3 groups had the same clinical stage basically. The expressions of c-Met, VEGF, EGFR and HER-2, CD34 were detected by immunohistochemistry (EnVision staining method). Tumor microvessel density (MVD) was calculated by marking CD34, and the results were analyzed. The clinicopathologic parameters were recorded accurately: gender, age, highest level of serum AFP, tumor differentiation, tumor stage, tumor location, lymph node metastasis, liver metastasis, Lauren classiifcation, etc. These patients were followed up regularly. The clinical pathological features of AFPGC patients were investigated.Results:AFPGC clinical characteristics showed that, among 44 cases of AFPGC group, 86.36% (38/44) had lymph node metastasis, 54.55% (24/44) had hepatic metastasis, intestinal type was 36.36% (16/44), diffuse type was 56.82% (25/44), mixed type was 6.82% (3/44). The positive expression rates of c-Met protein in AFPGC, gastric cancer with normal AFP, hepatocellular carcinoma with increased AFP were 73.33% (22/30), 70.00% (21/30) and 53.33% (16/30), respectively. The positive expression rates of VEGF protein were 76.67% (23/30), 56.67% (17/30) and 66.67% (20/30), respectively. The positive expression rates of EGFR protein were 53.33% (16/30), 40.00% (12/30) and 73.33% (22/30), respectively. The “++ and +++” expression rates of HER-2 in AFPGC, gastric cancer with normal AFP and hepatocellular carcinoma with increased AFP were 38.64% (17/44), 23.33% (7/30) and 26.67% (7/30), respectively. The MVD values in AFPGC, gastric cancer with normal AFP and hepatocellular carcinoma with increased AFP were 23.03±10.24, 21.92±11.45 and 19.43±7.83, respectively. Compared with gastric cancer with normal AFP, expression of VEGF protein was signiifcantly higher in the AFPGC (P<0.05). Compared with hepatocellular carcinoma with increased AFP, the expression of c-Met protein was significantly higher in AFPGC (P<0.05).Conclusion:AFPGC is prone to lymph node metastasis and hepatic metastasis. The major part is the diffuse type in Lauren classiifcation. The positive expression rates of VEGF protein in AFPGC were signiifcantly higher than the gastric cancer with normal AFP. The positive expression rates of c-Met protein in AFPGC were signiifcantly higher than the hepatocellular carcinoma with AFP increased.
4.Dosimetric comparison between RapidArc and fixed gantry dynamic IMRT for central-type lung cancer radiotherapy
Jian GONG ; Rong YU ; Hao WU ; Shukui HAN ; Bo XU ; Guangying ZHU ; Fan JIANG
Chinese Journal of Radiological Medicine and Protection 2010;30(4):448-451
Objective To compare the dosimetric difference between RapidArc and fixed gantry angle dynamic IMRT (dIMRT) for central-type lung cancer radiotherapy. Methods Therapy for 10 patients previously treated with dIMRT was replanned with RapidArc. Dose prescription was 66 Gy/33 fraction. Comparative endpoints were planning target volume (PTV) dose, doses to surrounding structures,number of monitor units, and treatment delivery time. Results There was no significant dosimetric difference between RapidArc and dIMRT. Compared with dIMRT, RapidArc slightly elevated target volume dose, lung V5, V10. The average values of lung V20, V30 and heart V30 were larger in dIMRT than those in RapidArc. The number of monitor units was reduced by 32% and the treatment time by 66% in RapidArc.Conclusions Both RapidArc and dIMRT plans could meet the clinical therapy needs. RapidArc could achieve similar target coverage and sparing of organs at risk, with fewer monitor units and shorter delivery time than dIMRT.
5.A study of the pepsin in the sputum for diagnosis and treatment evaluation of laryngopharyngeal reflux.
Shukui YU ; Yang CHEN ; Jianhua QIU ; Xiaona ZONG ; Xiaodong CHENG ; Feng PAN ; Wenjuan MI
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2011;25(13):604-607
OBJECTIVE:
To study the value of the pepsin in the sputum for diagnosing and evaluating the effectiveness of treatment of laryngopharyngeal reflux.
METHOD:
Thirty-six patients with the symptoms of dry pharynx, globus pharyngeus, excessive throat clearing, chronic cough and so on were divided into laryngopharyngeal reflux group and chronic laryngitis group by the results of therapeutic trial taking proton pump inhibitors for 3 months. The estimation of the reflux symptom index (RSI), the reflux finding score (RFS) and the detection of pepsin in the sputum were done before and after the treatment. The difference between two groups and the value of the pepsin were analyzed.
RESULT:
There were significant decreasing in RSI, RFS and pepsin level (P < 0.01) after the treatment in all patients. There were statistical differences between the laryngopharyngeal reflux group and the chronic laryngitis group in the changes of RSI and pepsin level (P < 0.01).
CONCLUSION
Pepsin level in the sputum might be used as a objective, effective method for diagnosing and evaluating the effectiveness in laryngopharyngeal reflux.
Adult
;
Female
;
Humans
;
Laryngopharyngeal Reflux
;
diagnosis
;
therapy
;
Male
;
Middle Aged
;
Pepsin A
;
analysis
;
Sputum
;
chemistry
;
Treatment Outcome
;
Young Adult
6.Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2020 Version).
Caicun ZHOU ; Jie WANG ; Baocheng WANG ; Ying CHENG ; Zhehai WANG ; Baohui HAN ; You LU ; Gang WU ; Li ZHANG ; Yong SONG ; Bo ZHU ; Yi HU ; Ziping WANG ; Qibin SONG ; Shengxiang REN ; Yayi HE ; Xiaohua HU ; Jian ZHANG ; Yu YAO ; Hongyun ZHAO ; Zhijie WANG ; Qian CHU ; Jianchun DUAN ; Jingjing LIU ; Shukui QIN
Chinese Journal of Lung Cancer 2021;24(4):217-235
Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The systemic antitumor therapy of advanced NSCLC has undergone renovations of chemotherapy, targeted therapy and immunotherapy, which results in greatly improved survival for patients with advanced NSCLC. Immune checkpoint inhibitors (ICIs), especially targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1), has changed the treatment paradigm of NSCLC. ICIs have become the standard treatment for advanced NSCLC without epidermal growth factor receptor(EGFR) mutation or anaplastic lymphomakinase(ALK) translocation in the first- or second-line setting, and for locally advanced NSCLC following concurrent radiotherapy and chemotherapy. ICIs are also promising in adjuvant/neoadjuvant therapy. More and more ICIs have been approved domestically for the treatment of NSCLC. Led by the NSCLC expert committee of Chinese Society of Clinical Oncology (CSCO), this consensus was developed and updated based on thoroughly reviewing domestic and foreign literatures, clinical trial data, systematic reviews, experts' discussion and the consensus(2019 version). This consensus will aid domestic clinicians in the treatment of NSCLC with ICIs.
.